I disagree. If the results are good, which most of us are expecting, especially given the recent announcements that Leronlimab patients had 63% less SAEs than the placebo patients, I think any short that's been paying attention will want to cover before Thursday.
FDA is continuing the trial unlike ‘many trials of other drugs so we are in great shape! NP doesn’t care about shorts anymore because he knows they have a winner. Hold on to your gold nuggets, no reason to sell.